In the letter of Moreau, 1 the result of a small trial of the treatment with rituximab as a single agent in patients with multiple myeloma (MM) that expresses CD20 is reported. In this trial, there is no benefit for the patients newly diagnosed or relapsed with CD20 þ MM. In a later letter of Gozzetti, 2 complete remission is reported in a single patient with CD20 þ MM refractory to high dose melphalan. This patient was treated with four courses of weekly rituximab addressing the possibility that a timing effect of rituximab could explain its activity. Notwithstanding these reports, no results of the combination treatment of chemotherapy plus rituximab in CD20 þ MM have been published.
We have recently treated a 47-year-old man with a relapsed MM with the combination of R-VAD (rituximab, vincristine, adriamycin and dexamethasone). The patient was diagnosed in 2001 with an IgA lambda MM, stage IIIA. The immunophenotype at the diagnosis in 2001 was CD45À, CD19À, CD20À, CD38 þ , CD138 þ , CD56 þ . He was treated according to the PETHEMA 2000 protocol consisting of six cycles of VBAD/ VCMP (vincristine, bleomycin, adriamycin, dexamethasone, cyclophosphamide, melphalan, prednisone) followed by peripheral blood stem cell transplantation. The patient remained in complete remission until the disease relapsed in November 2005. In February 2006, the patient was treated with eight cycles of bortezomib and dexamethasone. Bortezomib plus dexamethasone did not work either, and at the end of the therapy clinical performance was poor, with intense bone pain and a great lytic lesion in the distal right femur's epiphysis. Bone marrow examination showed a massive infiltration by 92% of atypical, large plasmatic cells, with cytoplasmatic blebs and frequent multinuclearity. Monoclonal IgA kappa and severely depressed IgG and IgM inmunoglobulins were observed. Immunophenotype of the MM cells at relapse and after eight cycles of bortezomib was CD45À, CD20 þ , CD19À, CD38 bright, CD138 þ , CD56À (Figure 1 ). The patient was treated with four cycles of R-VAD (rituximab 375 mg m -2 , VAD in standard dose). The first cycle of R-VAD was complicated with lysis syndrome (uric acid 13 mg per 100 ml, creatinine 3.4 mg per 100 ml). Clinically, the patient improved after the first cycle. At the end of four cycles, no minimally residual disease (CD20 þ , CD38 þ , CD138 þ MM cells) was found either in immunophenotype, bone marrow aspiration or biopsy even though the bone marrow was hypocellular. In March 2007, autologous stem cell transplantation was performed using a peripheral blood apheresis obtained in 2001. Conditioning regimen was melphalan at 200 mg m -2 and 3.4 Â 10 6 CD34 cells were infused. Neutrophil recovery occurred at eighth day after apheresis product infusion; platelet number recovery up to 100 Â 10 9 /l was reached 2 months after stem cell transplanta- Letters to the Editor tion. Now, 5 months after stem cell transplantation, the patient is in complete remission and in good physical performance.
The activity of rituximab in unselected patients with MM was supposedly based on the presence of clonotypic B-cell precursor plasma cells that express CD20. 3 This hypothesis, disappointingly, was not confirmed in small trials. 4, 5 In the work of Moreau, using selected CD20 þ MM patients, rituximab as single agent was not effective. In our patient, relapse had the characteristics of the final phase of MM: massive bone marrow infiltration; clinical aggressiveness; plasmablastic morphology; change in immunophenotype and refractory disease to the combination of bortezomib and dexamethasone corroborate this point of view. The use in this case of rituximab plus VAD was impressive in the first cycle. We think that the use of rituximab in combination with some type of concurrent chemotherapy like VAD, merits further trials in patients with positive CD20 þ MM, and as in the case of B-lymphoma, synergism might be found. Unfortunately the scarcity of patients with CD20 þ MM who can be enrolled in a trial limits the capacity of unraveling the more effective association and drug schedule.
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We agree with Bergua et al. 1 on the possible superior efficacy of combination therapy treatment with rituximab and chemotherapy in CD20-positive multiple myeloma, with respect to rituximab alone, due to its synergism with many cytotoxic drugs. Nevertheless, the intention of our case report 2 was to highlight a possible role of subsequent immunotherapy after debulking with chemotherapy to reduce the residual disease. Of note, a strict follow-up in our patient showed the disease recurrence (10% of bone marrow monoclonal plasma cells) again, 6 months after rituximab interruption. We believe that optimal timing of anti-CD20 treatment in this subset of myeloma patients has still to be determined with a possible role for maintenance therapy. 
